vs
Side-by-side financial comparison of Azenta, Inc. (AZTA) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $148.6M, roughly 1.2× Azenta, Inc.). AMICUS THERAPEUTICS, INC. runs the higher net margin — 0.9% vs -10.4%, a 11.3% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 0.8%). AMICUS THERAPEUTICS, INC. produced more free cash flow last quarter ($16.0M vs $14.7M). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 4.4%).
Azenta, was founded in 1978, and is based in Chelmsford, Massachusetts, United States. The company is a provider of life sciences services including genomics, cryogenic storage, automation, and informatics.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
AZTA vs FOLD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.6M | $185.2M |
| Net Profit | $-15.4M | $1.7M |
| Gross Margin | 42.9% | 85.7% |
| Operating Margin | -4.9% | 8.6% |
| Net Margin | -10.4% | 0.9% |
| Revenue YoY | 0.8% | 23.7% |
| Net Profit YoY | -15.7% | -88.5% |
| EPS (diluted) | $-0.34 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.6M | $185.2M | ||
| Q3 25 | $159.2M | $169.1M | ||
| Q2 25 | $143.9M | $154.7M | ||
| Q1 25 | $143.3M | $125.2M | ||
| Q4 24 | $147.4M | $149.7M | ||
| Q3 24 | $150.6M | $141.5M | ||
| Q2 24 | $144.3M | $126.7M | ||
| Q1 24 | $136.4M | $110.4M |
| Q4 25 | $-15.4M | $1.7M | ||
| Q3 25 | $50.9M | $17.3M | ||
| Q2 25 | $-48.0M | $-24.4M | ||
| Q1 25 | $-47.7M | $-21.7M | ||
| Q4 24 | $-11.0M | $14.7M | ||
| Q3 24 | $-6.6M | $-6.7M | ||
| Q2 24 | $-6.6M | $-15.7M | ||
| Q1 24 | $-137.4M | $-48.4M |
| Q4 25 | 42.9% | 85.7% | ||
| Q3 25 | 45.4% | 88.5% | ||
| Q2 25 | 46.2% | 90.2% | ||
| Q1 25 | 43.8% | 90.7% | ||
| Q4 24 | 46.7% | 90.1% | ||
| Q3 24 | 45.5% | 90.6% | ||
| Q2 24 | 44.8% | 91.1% | ||
| Q1 24 | 43.8% | 87.7% |
| Q4 25 | -4.9% | 8.6% | ||
| Q3 25 | 1.2% | 20.3% | ||
| Q2 25 | -1.3% | -6.1% | ||
| Q1 25 | -12.7% | -6.3% | ||
| Q4 24 | -5.9% | 10.7% | ||
| Q3 24 | -3.1% | 15.3% | ||
| Q2 24 | -4.9% | 11.8% | ||
| Q1 24 | -18.1% | -25.1% |
| Q4 25 | -10.4% | 0.9% | ||
| Q3 25 | 32.0% | 10.2% | ||
| Q2 25 | -33.4% | -15.8% | ||
| Q1 25 | -33.3% | -17.3% | ||
| Q4 24 | -7.5% | 9.8% | ||
| Q3 24 | -4.4% | -4.8% | ||
| Q2 24 | -4.5% | -12.4% | ||
| Q1 24 | -100.8% | -43.9% |
| Q4 25 | $-0.34 | $0.00 | ||
| Q3 25 | $1.12 | $0.06 | ||
| Q2 25 | $-1.05 | $-0.08 | ||
| Q1 25 | $-1.04 | $-0.07 | ||
| Q4 24 | $-0.25 | $0.05 | ||
| Q3 24 | $-0.25 | $-0.02 | ||
| Q2 24 | $-0.12 | $-0.05 | ||
| Q1 24 | $-2.48 | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $336.6M | $293.5M |
| Total DebtLower is stronger | — | $392.7M |
| Stockholders' EquityBook value | $1.7B | $274.2M |
| Total Assets | $2.1B | $949.9M |
| Debt / EquityLower = less leverage | — | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $336.6M | $293.5M | ||
| Q3 25 | $279.8M | $263.8M | ||
| Q2 25 | $270.0M | $231.0M | ||
| Q1 25 | $253.6M | $250.6M | ||
| Q4 24 | $377.5M | $249.9M | ||
| Q3 24 | $280.0M | $249.8M | ||
| Q2 24 | $336.5M | $260.1M | ||
| Q1 24 | $353.5M | $239.6M |
| Q4 25 | — | $392.7M | ||
| Q3 25 | — | $392.0M | ||
| Q2 25 | — | $391.3M | ||
| Q1 25 | — | $390.7M | ||
| Q4 24 | — | $390.1M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $388.9M | ||
| Q1 24 | — | $388.4M |
| Q4 25 | $1.7B | $274.2M | ||
| Q3 25 | $1.7B | $230.4M | ||
| Q2 25 | $1.7B | $204.3M | ||
| Q1 25 | $1.7B | $193.6M | ||
| Q4 24 | $1.7B | $194.0M | ||
| Q3 24 | $1.8B | $178.8M | ||
| Q2 24 | $2.0B | $132.5M | ||
| Q1 24 | $2.2B | $130.7M |
| Q4 25 | $2.1B | $949.9M | ||
| Q3 25 | $2.1B | $868.8M | ||
| Q2 25 | $2.0B | $815.3M | ||
| Q1 25 | $2.0B | $789.8M | ||
| Q4 24 | $2.0B | $785.0M | ||
| Q3 24 | $2.1B | $786.6M | ||
| Q2 24 | $2.3B | $749.5M | ||
| Q1 24 | $2.6B | $721.8M |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | — | 2.01× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.93× | ||
| Q1 24 | — | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.8M | $16.3M |
| Free Cash FlowOCF − Capex | $14.7M | $16.0M |
| FCF MarginFCF / Revenue | 9.9% | 8.6% |
| Capex IntensityCapex / Revenue | 4.2% | 0.2% |
| Cash ConversionOCF / Net Profit | — | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | $30.9M | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.8M | $16.3M | ||
| Q3 25 | $2.2M | $35.7M | ||
| Q2 25 | $25.8M | $-26.5M | ||
| Q1 25 | $14.4M | $7.8M | ||
| Q4 24 | $29.8M | $-3.9M | ||
| Q3 24 | $17.7M | $-23.0M | ||
| Q2 24 | $9.8M | $22.7M | ||
| Q1 24 | $8.7M | $-29.7M |
| Q4 25 | $14.7M | $16.0M | ||
| Q3 25 | $-5.7M | $35.3M | ||
| Q2 25 | $15.0M | $-28.9M | ||
| Q1 25 | $7.0M | $7.5M | ||
| Q4 24 | $22.0M | $-4.2M | ||
| Q3 24 | $8.3M | $-23.3M | ||
| Q2 24 | $1.3M | $21.6M | ||
| Q1 24 | $428.0K | $-31.5M |
| Q4 25 | 9.9% | 8.6% | ||
| Q3 25 | -3.6% | 20.9% | ||
| Q2 25 | 10.4% | -18.7% | ||
| Q1 25 | 4.9% | 6.0% | ||
| Q4 24 | 15.0% | -2.8% | ||
| Q3 24 | 5.5% | -16.5% | ||
| Q2 24 | 0.9% | 17.0% | ||
| Q1 24 | 0.3% | -28.5% |
| Q4 25 | 4.2% | 0.2% | ||
| Q3 25 | 4.9% | 0.2% | ||
| Q2 25 | 7.5% | 1.6% | ||
| Q1 25 | 5.2% | 0.2% | ||
| Q4 24 | 5.3% | 0.2% | ||
| Q3 24 | 6.2% | 0.3% | ||
| Q2 24 | 5.9% | 0.9% | ||
| Q1 24 | 6.1% | 1.6% |
| Q4 25 | — | 9.62× | ||
| Q3 25 | 0.04× | 2.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AZTA
| Multiomics | $67.2M | 45% |
| Core Products | $47.6M | 32% |
| Sample Repository Solutions | $33.8M | 23% |
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
